Endometriosis Market to Accelerate Substantially at a CAGR of 5.3% During the Study Period (2019-2032), Assesses DelveInsight

News provided by

Jan 25, 2023, 10:35 ET

The growth of the endometriosis market is expected to be mainly driven by the entry of novel therapies with better clinical profiles, an upsurge in research and development, and an enriched understanding of the disease

LAS VEGAS, Jan. 25, 2023 /PRNewswire/ -- DelveInsight's Endometriosis Market Insights report includes a comprehensive understanding of current treatment practices, endometriosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (France, Italy, Germany, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Endometriosis Market Report

As per DelveInsight analysis, the endometriosis market size in the 7MM was approximately USD 1,920 million in 2021.
According to the assessment done by DelveInsight, the estimated total endometriosis prevalent cases in the 7MM was approximately 22 million in 2021.
Leading companies such as AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, and others are developing novel endometriosis drugs that can be available in the endometriosis market in the coming years.
The promising endometriosis therapies in the pipeline include ORIAHNN (elagolix/estradiol/norethindrone acetate), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others.
In April 2022, HMI-115 received an MoH application for the first European country.

Discover which therapies are expected to grab the major endometriosis market share @ Endometriosis Market Report

Endometriosis Overview

Endometriosis is a condition in which endometrium patches appear in places other than the womb, such as the fallopian tubes, ovaries, or lungs. It is an idiopathic condition; possible causes include retrograde menstruation, peritoneal cell transformation, embryonic cell transformation, surgical scar implantation, endometrial cell transport, immune system disorder, and so on. Several factors, such as never giving birth, early menarche, late menopause, short menstrual cycles, genetics (mother, aunt, or sister) with endometriosis, reproductive tract disorders, and so on, increase the risk of developing endometriosis.

Endometriosis symptoms and signs include dysmenorrhea, pain during intercourse, pain during bowel movements or urination, excessive bleeding, infertility, and others. Endometriosis diagnosis is typically based on patient history or physical exam, and diagnostic tools such as laparoscopy, biopsy, ultrasound, MRI, and others are used.

Endometriosis Epidemiology Segmentation

DelveInsight estimates that there were approximately 22 million prevalent cases of endometriosis in the 7MM in 2021.

In 2021, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of endometriosis, i.e., ~ 4.7 million, which is expected to increase by 2032.

The endometriosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Prevalent cases
Diagnosed prevalent cases
Age-specific diagnosed prevalent cases
Diagnosed prevalent cases of endometriosis by pain severity
Total treated cases

Download the report to understand which factors are driving endometriosis epidemiology trends @ Endometriosis Epidemiological Insights

Endometriosis Treatment Market

Endometriosis is currently treated with surgical removal of endometriotic lesions via laparoscopy, which reduces pain and increases pregnancy rates, and therapeutics that suppress pain, ovarian function, and estrogen action. Oral contraceptives (off-label), progestins as first-line pharmacological treatment, and GnRH agonists/antagonists as second-line endometriosis treatment are available. The latter option causes hypoestrogenism and has serious side effects such as drug-induced menopause and osteoporosis.

All of these endometriosis treatments, most importantly, prevent fertility. Persistent pain, a common and debilitating symptom of endometriosis, is commonly treated with NSAIDs, which have variable efficacy and serious side effects when used for an extended period. There is an unmet clinical need for new non-hormonal endometriosis treatments.

ORILISSA (elagolix) was the first FDA-approved oral treatment for moderate-to-severe endometriosis pain. ORILISSA comes in two oral doses: 150 mg once daily and 200 mg twice daily. ORILISSA 150 mg tablets are oblong, light pink, film-coated tablets with "EL 150" debossed on one side. Moreover, MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is a once-daily tablet that is taken orally. MYFEMBREE contains relugolix, which lowers the amount of estrogen (and other hormones) produced by the ovaries; estradiol (an estrogen), which may reduce the risk of bone loss; and norethindrone acetate (a progestin), which is required when women with uteruses (wombs) take estrogen. The FDA approved it in August 2022.

To know more about endometriosis treatment guidelines, visit @ Endometriosis Management

Endometriosis Pipeline Therapies and Key Companies

ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
OVAREST (leuprorelin oral): SWK/Enteris BioPharma
HMI-115: Bayer/Hope Medicine
TU2670 (NCE-403): Tiumbio
OG-6219: Organon

Learn more about the FDA-approved drugs for endometriosis @ Drugs for Endometriosis Treatment

Endometriosis Market Dynamics

The dynamics of the endometriosis market are anticipated to change in the coming years owing to the improvement healthcare spending worldwide. Moreover, the rising prevalence of endometriosis is the primary strength of its global endometriosis market, prompting pharmaceutical companies to increase their focus. In addition, the increasing prevalence of endometriosis creates a larger window of opportunity for new endometriosis treatment options for women suffering from this disease.

Furthermore, the availability of patient assistance programs for expensive drugs by companies such as Bayer and AbbVie is expected to increase patient adherence to such drugs, driving the endometriosis market over the forecast period. In addition, incumbents are paired with healthcare providers to raise endometriosis awareness among physicians and patients.

However, several factors are impeding the growth of the endometriosis market. Patients who could benefit from symptomatic medical management are not always treated because primary healthcare providers are unaware of endometriosis. Moreover, endometriosis has a high economic burden compared to other chronic diseases. It is caused primarily by a decrease in productivity and is predicted by a decrease in quality of life.

Furthermore, the endometriosis market is rife with off-label medications and is still heavily genericized, posing a significant barrier to novel therapy entrants. Due to diagnostic delays, patients frequently do not receive timely access to available treatment methods such as nonsteroidal analgesics (pain relievers), oral contraceptives, and progestin-based contraceptives. Thus, all these factors mentioned above will hamper the endometriosis market growth in the future.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Base Year	2019
Endometriosis Market CAGR	5.3 %
Endometriosis Market Size in 2021	USD 1,920 Million
Key Endometriosis Companies	AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, and others
Key Pipeline Endometriosis Therapies	ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others

Scope of the Endometriosis Market Report

Therapeutic Assessment: Endometriosis current marketed and emerging therapies
Endometriosis Market Dynamics: Endometriosis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Endometriosis Market Access and Reimbursement

Discover more about endometriosis drugs in development @ Endometriosis Clinical Trials

Table of Contents

1.	Endometriosis Market Key Insights
2.	Endometriosis Market Report Introduction
3.	Endometriosis Market Overview at a Glance
4.	Endometriosis Market Executive Summary
5.	Disease Background and Overview
6.	Endometriosis Treatment and Management
7.	Endometriosis Epidemiology and Patient Population
8.	Patient Journey
9.	Endometriosis Marketed Drugs
10.	Endometriosis Emerging Drugs
11.	Seven Major Endometriosis Market Analysis
12.	Endometriosis Market Outlook
13.	Potential of Current and Emerging Therapies
14.	KOL Views
15.	Endometriosis Market Drivers
16.	Endometriosis Market Barriers
17.	Unmet Needs
18.	SWOT Analysis
19.	Appendix
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

Related Reports

Endometriosis Pipeline

Endometriosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others.

Endometriosis Epidemiology Forecast

Endometriosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Endometriosis Pain Market

Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.

Endometriosis Pain Pipeline

Endometriosis Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.

Endometrial Cancer Market

Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including GlaxoSmithKline, Eisai Co Ltd, MedImmune, On Target Laboratories, Sutro Biopharma, among others.

Endometrial Cancer Pipeline

Endometrial Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometrial cancer companies, including GlaxoSmithKline, Eisai Co Ltd, MedImmune, On Target Laboratories, Sutro Biopharma, among others.

Other Trending Reports

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services

Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research LLP